Treatment of EGFR mutant lung cancers with EGFR-TKIs effectively inhibits tumor progression and prolongs progression free survival (PFS) in patients with NSCLC compared with standard chemotherapeutic agents (Schrank et al., 2018). Here, EGFR is linked to lung cancer.